Edition:
India

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

30.08USD
1:30am IST
Change (% chg)

$-0.20 (-0.66%)
Prev Close
$30.28
Open
$30.56
Day's High
$31.49
Day's Low
$29.95
Volume
77,209
Avg. Vol
41,766
52-wk High
$86.67
52-wk Low
$29.38

Latest Key Developments (Source: Significant Developments)

ANI Pharmaceuticals Announces Launch Of Paliperidone Extended-Release Tablets
Tuesday, 14 Jan 2020 

Jan 14 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS INC - LAUNCH OF PALIPERIDONE EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG AND 9 MG.  Full Article

ANI Pharmaceuticals Enters Distribution Agreement With A U.S. Based Injectable Manufacturer
Monday, 15 Apr 2019 

April 15 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS EXPANDS INJECTABLE PORTFOLIO WITH DISTRIBUTION AGREEMENT FOR FDA APPROVED INJECTABLE PRODUCT.ANI PHARMACEUTICALS INC - DISTRIBUTION AGREEMENT WITH A U.S. BASED INJECTABLE MANUFACTURER TO COMMERCIALIZE A UNIQUE SPECIALTY INJECTABLE PRODUCT.ANI PHARMACEUTICALS INC - KEY TERMS OF 10-YEAR AGREEMENT INCLUDE CUMULATIVE MILESTONES OF UP TO $2M, PAYABLE BY ANI.ANI PHARMACEUTICALS INC - UPON LAUNCH, ANI WILL RECEIVE A 50% SHARE OF NET PROFITS GENERATED FROM PRODUCT REVENUES.ANI PHARMACEUTICALS INC - SPECIALTY INJECTABLE PRODUCT WILL BE COMMERCIALIZED IN ANI LABEL.  Full Article

ANI Pharmaceuticals Reports Q4 and FY2018 Results, Provides 2019 Guidance
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR AND FOURTH QUARTER 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 REVENUE $57.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.5 MILLION.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $5.07.Q4 GAAP EARNINGS PER SHARE $1.30.Q4 EARNINGS PER SHARE ESTIMATE $1.24 -- REFINITIV IBES DATA.SEES 2019 NET REVENUES OF $231 MILLION TO $245 MILLION.SEES 2019 ADJUSTED NON-GAAP EBITDA OF $95 MILLION TO $105 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.57 TO $6.21.FY2019 EARNINGS PER SHARE VIEW $5.79, REVENUE VIEW $243.4 MILLION -- REFINITIV IBES DATA.  Full Article

ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.32
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR AND FOURTH QUARTER 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 REVENUE $57.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.5 MILLION.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.32.Q4 GAAP EARNINGS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $1.24 -- REFINITIV IBES DATA.SEES 2019 NET REVENUES OF $231 MILLION TO $245 MILLION.SEES 2019 ADJUSTED NON-GAAP EBITDA OF $95 MILLION TO $105 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.57 TO $6.21.FY2019 EARNINGS PER SHARE VIEW $5.79, REVENUE VIEW $243.4 MILLION -- REFINITIV IBES DATA.  Full Article

Ani Pharmaceuticals To Repurchase $25 Mln Aggregate Principal Amount Of Notes
Friday, 7 Dec 2018 

Dec 7 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS INTO SEPARATE PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF ITS CONVERTIBLE NOTES.ANI PHARMACEUTICALS-ENTERED INTO SEPARATE, PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF OUTSTANDING 3.00% CONVERTIBLE SENIOR NOTES DUE 2019.ANI PHARMACEUTICALS INC - AGREED TO REPURCHASE $25.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES FOR A TOTAL OF $26.1 MILLION IN CASH.ANI PHARMACEUTICALS INC - ANI HAS ALSO ENTERED INTO AN AGREEMENT WITH DEALER PARTY TO CERTAIN CONVERTIBLE NOTE HEDGE TRANSACTIONS.ANI PHARMACEUTICALS INC - ALSO ENTERED INTO AGREEMENTS WITH SUCH DEALER COUNTERPARTY TO UNWIND CERTAIN WARRANT TRANSACTIONS.  Full Article

BRIEF-ANI Pharmaceuticals Says Making Progress To Address Items Identified In FDA's Refusal To File Letter Relating To Cortrophin Gel sNDA Filing

* ANI PHARMACEUTICALS - CONTINUES TO MAKE PROGRESS TO ADDRESS ITEMS IDENTIFIED IN FDA'S REFUSAL TO FILE LETTER RELATING TO CORTROPHIN GEL SNDA FILING